Navigation Links
Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
Date:11/4/2008

LAKE FOREST, Ill., Nov. 4 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced that Christopher B. Begley, chairman and chief executive officer, and Thomas E. Werner, senior vice president, Finance, and chief financial officer, will make a formal presentation at the 2008 Annual Credit Suisse Health Care Conference on Wednesday, Nov. 12, 2008, in Phoenix.

The presentation is scheduled to begin at noon Mountain time on Wednesday, Nov. 12, 2008. It will be available to all interested parties through a live audiocast accessible via the investor relations section of Hospira's Web site at http://www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup to receive the audiocast. The slides accompanying the presentation will be available on the Hospira Web site. A replay of the webcast will be available on the Hospira Web site approximately 24 hours after the live presentation.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
2. Hospira Announces New Contracts With Premier Purchasing Partners for Infusion Devices, Solutions And Equipment
3. Hospira Reports Second-Quarter 2008 Results
4. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
5. Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders
6. Hospira to Present at the Bank of America 2008 Health Care Conference on May 14
7. Hospira Acquires Sculptor
8. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
9. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
10. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
11. Hospira Launches Generic Irinotecan Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... on cholesterol treatment and cardiovascular risk assessment state that ... from atherosclerotic cardiovascular disease or of having a heart ... risk profile (based on age, smoking history, and cholesterol ... for when and how aggressively to treat high cholesterol ... Men,s Health , a peer-reviewed publication from Mary Ann ...
(Date:7/22/2014)... (LALCA 2014) will be held August 21 23, ... the leading cause of death not only in Latin ... previous conferences in Chile, Mexico, Argentina and Brazil, international ... in the treatment and prevention of lung cancer and ... With tobacco being the leading cause of morbi-mortality worldwide ...
(Date:7/22/2014)... The Beryl Institute announces its fifth annual ... Program. These offerings reinforce the Institute’s commitment to support ... and the need for rigorous research to understand and ... programs are intended to encourage and support research ... on the patient experience before, during and after care ...
(Date:7/22/2014)... Ticket Down is a reliable source for cheap Manchester ... MD. There has never been a better time in the ... success of the American national soccer team at the 2014 World ... that fans of the world’s sport will be able to feed ... Champions Cup. The tournament will kick off on July 24 and ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4
... taking the contraceptive pill may find themselves less responsive to ... The study, published in the journal Human Reproduction, measured the ... - while taking and not taking the Pill. ... experienced rises and falls in their ability to sense smells, ...
... vocal cords improves voice problems in Parkinson's disease. One of ... voice quality experienced by some patients. This problem is known ... abnormalities in the area of the voice box or larynx.// ... may be hard to understand what they are saying. You ...
... might explain common digestive symptoms like gas, pain and ... the link between fructose intolerance and the symptoms of ... abdominal discomfort, bloating and changes in bowel habit. Fructose ... honey. Some people can't digest it, but the condition ...
... past evidence that hormone replacement might lower stroke risk ... does not protect women from recurrent strokes and may ... evidence that hormone replacement therapy does not have the ... doctors have long thought hormone replacement therapy might help ...
... cheese and whole milk may be at increased risk ... The rates of two types of cancer--gastric cardia and ... 30 years. To investigate potential links between these and ... dietary factors, Dr. Susan T. Mayne from Yale University ...
... who undergo surgery for breast cancer will experience ... surgery, according to new research. Dr. Erica S. ... colleagues reported the findings at the American Public ... researchers asked 266 women who had undergone breast ...
Cached Medicine News:
(Date:7/22/2014)... , July 22, 2014  ConvaTec, a privately-held medical ... Clerkin has been appointed chief financial officer of ... Clerkin was previously executive vice president and chief financial ... -based biotechnology company.  Mr. Clerkin was part of a ... Elan, culminating in its sale to Perrigo, a pharmaceutical ...
(Date:7/22/2014)... , July 22, 2014  UL (Underwriters ... that the U.S. Food and Drug Administration (FDA) ... consensus standards for medical devices incorporating lithium or ... - Standard for Household and Commercial Batteries, and ... Consensus standards are standards recognized ...
(Date:7/22/2014)... York , July 22, 2014 ... Partnerschaft für umfassenden Schutz von Pharmazeuten ... Österreich    Equashield ( ... Transfersystemen (Closed System Transfer Devices, CSTDs) für gefährliche ... einen Vertriebshändler und Hersteller von medizinischen ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Curis, ... novel targeted,medicines primarily for cancer treatment, today ... presentations at the 98th Annual Meeting,of the ... AACR, Curis also disclosed that its April ...
... 17, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced the ... clinical trial of the triplet combination of ... the,first-line treatment of advanced non-small cell lung ... significant,improvement in both progression-free survival and overall ...
Cached Medicine Technology:Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4
... Mammography has been FDA approved, and represents ... It is the first and only mammography ... - the highest available. SenoScan's larger field ... breast support is more comfortable and helps ...
... The P3000 heralds a new concept in pupillometry, ... infrared optical system developed for the P2000. ... in which we have paid particular attention to ... Our new system is extremely flexible, allowing you ...
... the most useful features is the PupilFit ... mathematical analysis of the pupil images, producing ... instantaneously. The fitted circle is shown as ... proof that the measurement ismeaningful, and not ...
... An easy-to-operate, semi-automatic urine analyzer that ensures ... your lab efficiency by reducing "hands on" ... makes it an ideal fit for work ... Criterion II Analyzer is designed for continuous ...
Medicine Products: